Angiotensin-converting enzyme inhibitors (ACEIs) was demonstrated protective effect for patients with mild to moderate chronic kidney disease (CKD). The ACEIs was usually applied to patients while his serum creatinine (Scr) levels were no more than 3.0 mg/dL. However, it could induce AKI even in the patients with mild to moderate CKD combined with CHF. We report a case of a 62-year-old male with CHF and moderate CKD (SCr: 1.9 mg/dL) who subsequently and transiently develop AKI after he was administrated benazepril 2.5mg/day. Using the Naranjo, benazepril was found to be a probable cause of AKI in the patient. ACEIs, classified as RAAS inhibitors, can induce AKI in some conditions. Attention should be given to benazepril therapy in patients with mild to moderate CKD and CHF. Routine hemodynamic examination and biochemical monitoring was suggested before and during the period of benazepril therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.